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1. Summary
The presence of foetal DNA in the plasma of pregnant women has opened up
new possibilities for non-invasive prenatal diagnosis. The use of circulating
foetal DNA for the non-invasive prenatal detection of foetal chromosomal
aneuploidies is challenging as foetal DNA represents a minor fraction of
maternal plasma DNA. In 2007, it was shown that single molecule counting
methods would allow the detection of the presence of a trisomic foetus, as
long as enough molecules were counted. With the advent of massively parallel
sequencing, millions or billions of DNA molecules can be readily counted.
Using massively parallel sequencing, foetal trisomies 21, 13 and 18 have been
detected from maternal plasma. Recently, large-scale clinical studies have vali-
dated the robustness of this approach for the prenatal detection of foetal
chromosomal aneuploidies. A proof-of-concept study has also shown that a
genome-wide genetic and mutational map of a foetus can be constructed
from the maternal plasma DNA sequencing data. These developments suggest
that the analysis of foetal DNA in maternal plasma would play an increasingly
important role in future obstetrics practice. It is thus a priority that the ethical,
social and legal issues regarding this technology be systematically studied.
2. Introduction
Prenatal diagnosis is now an established part of modern obstetrics practice.
However, conventional definitive methods for prenatal diagnosis involve the
invasive sampling of foetal tissues, using methods such as amniocentesis and
chorionic villus sampling (CVS). Such methods carry with them a small, but
definite risk for the foetus [1]. Ultrasound scanning and maternal serum bio-
chemical analysis have emerged as non-invasive methods for screening for
foetal chromosomal aneuploidies, such as trisomy 21 [2]. However, for the
detection of foetal chromosomal aneuploidies, such methods measure epiphe-
nomena, which are associated with the disorders, rather than analysing the
core pathology. As a result, they typically can only be used within a relatively
narrow gestational age window, and despite their development over many
years, their sensitivity and specificity still have much room for improvement.
Because of these limitations, there has been a search over the last few dec-
ades for safe, non-invasive methods for prenatal diagnosis that can allow the
direct analysis of foetal genetic materials. Early work had focused on the iso-
lation of foetal nucleated cells that had entered into the maternal blood.
However, the concentrations of such cells are very low, typically of the order
of one or a few foetal nucleated cells per millilitre of maternal blood [3]. Prob-
ably as a result of such low concentrations, prenatal testing carried out using
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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author and source are credited.circulating foetal cells has been found to have relatively low
sensitivity and specificity [4].
In 1997, Lo et al. were inspired by the presence of tumour-
derived DNA in the plasma and serum of cancer patients
[5,6], and wondered whether an analogous phenomenon
might also be present in pregnancy. Lo et al. were able to
find Y chromosomal DNA sequences in the plasma and
serum of women carrying male foetuses, and concluded
that cell-free foetal DNA was present in maternal plasma
and serum [7]. Subsequent measurements using real-time
polymerase chain reaction (PCR) have indicated that cell-
free foetal DNA is present in maternal plasma at a mean
fractional concentration of 3 per cent in the first and second
trimesters [8]. More recent measurements using more accu-
rate digital PCR-based techniques show that the median
fractional concentration may be approximately 10 per cent
[9]. Such relatively high fractional foetal DNA concentrations,
when compared with the fractional concentrations of foetal
nucleated cells in maternal blood, suggest that non-invasive
prenatal diagnosis carried out using the former would prob-
ably be more robust. Another advantage of the use of foetal
DNA in maternal plasma, compared with circulating foetal
nucleated cells, is the lack of persistence of the former follow-
ing delivery [10,11]. Conversely, there are numerous reports
describing the persistence of foetal nucleated cells in the
maternal circulation following delivery [12].
The robustness of non-invasive prenatal diagnosis using
cell-free foetal DNA in maternal plasma can be seen by the
many reports that describe diagnostic tests based on the
detection of DNA sequences that the foetus has inherited
from the father and which are absent in the maternal
genome. Examples include the detection of foetal sex based
on the detection of Y chromosomal DNA from maternal
plasma [13] and the detection of the RHD gene of a Rhesus
D-positive foetus in the plasma of a Rhesus D-negative
pregnant woman [14,15].
3. The challenge for the detection of foetal
chromosomal aneuploidies
The detection of foetal chromosomal aneuploidies, such as
trisomy 21, is much more challenging than the determination
of foetal sex and Rhesus D blood group genotype because,
apart from detecting the presence of foetal DNA in maternal
plasma, one also has to measure the foetal chromosome
dosage involving the chromosome of interest. The latter
task is made more difficult because of the fact that foetal
DNA is present as a minor fraction of the DNA that is
found in maternal plasma [8,9].
Early work has focused on the analysis of a subset of
nucleic acids present in maternal plasma that is foetal-
specific. Examples include DNA molecules bearing
foetal-specific DNA methylation patterns [16–19] and RNA
molecules that are specifically transcribed from the placenta
[20]. All but one [19] of the above-mentioned methods
involve the use of genetic polymorphisms and necessitate
the use of multiple markers to achieve a broad population
coverage. The method that does not require the use of genetic
polymorphisms is based on chromatin immunoprecipitation
and complex data normalization procedures [19]. These
steps would be challenging to be reproducibly performed
for a clinical diagnostic or a screening test. Another approach
that has been described involves the enrichment of the frac-
tional concentration of foetal DNA. One way to achieve
such enrichment uses the observation that foetal DNA mol-
ecules in maternal plasma are shorter than the maternally
derived ones [21,22]. However, the amount of enrichment
that one could achieve thus far using this approach is rela-
tively limited. Another method that has been reported
involves the use of formaldehyde on maternal blood samples.
This method has been claimed to minimize the release of
DNA from the maternal blood cells and thus to result in a
higher fractional concentration of foetal DNA in the plasma
fraction [23,24]. However, this method has not been
reproduced by a number of laboratories [25,26].
4. Molecular counting approach
An alternative approach for the detection of foetal chromoso-
mal aneuploidies is to measure the quantitative perturbations
in the genomic representation of the involved chromosome in
maternal plasma. However, the challenge is that such pertur-
bations are generally very small and are related to the
fractional concentration of circulating foetal DNA [27]. For
example, it has been shown that when the fractional foetal
DNA concentration is 10 per cent, the genomic representation
of chromosome 21 in maternal plasma will be increased by
5 per cent by the presence of a trisomy 21 foetus. The detec-
tion of such a small amount of quantitative perturbation
requires the use of extremely precise measurement methods.
In 2007, it was demonstrated that single-molecule counting
techniques using digital PCR as an example can be used for
such a purpose [27,28]. Such an approach was first realized
using plasma foetal (placenta-derived) RNA that is present
in maternal plasma [27]. The potential extension of this
approach to plasma DNA was also explored using DNA mix-
tures and computer simulations [27,28]. The numbers of
molecules that one would need to be counted for different
fractional foetal DNA concentrations have been outlined.
For example, it is suggested that to achieve the detection of
a trisomy 21 foetus in a maternal plasma sample containing
25 per cent foetal DNA would require the performance of
7680 digital PCRs. Furthermore, for every twofold reduction
in the fractional concentration of foetal DNA, the number of
molecules that one would need to count would increase by 2
2
(i.e. 4) times [27].
5. Non-invasive prenatal diagnosis by
massively parallel sequencing
With the advent of massively parallel sequencing, it has
become relatively easy to count millions (or even billions)
of DNA molecules [29]. In 2008, two groups showed that
the massively parallel sequencing of maternal plasma DNA
would allow one to work out the genomic representations
of different chromosomes in maternal plasma and to detect
the perturbations of such representations when a pregnant
woman is carrying a trisomic foetus [30,31]. This approach
involves the random sequencing of millions of DNA mol-
ecules in maternal plasma. Individual sequence tags are
aligned to the human genome to determine the chromosome
of origin of a particular sequence tag. The sensitivity and
specificity of these early reports, involving a relatively small
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2number of samples, are both 100 per cent. It has been shown
that both sequencing-by-synthesis [30,31] and sequencing-by-
ligation [32] platforms would work for this approach. The
method is also applicable for foetal trisomy 21 that is
caused by a Robertsonian translocation [33].
The throughput of the use of massively parallel sequen-
cing for the detection of foetal trisomy 21 has since then
been validated by a number of large-scale clinical studies
[34–37]. The detection of foetal trisomies 13 and 18 has
been shown to be more challenging owing to the GC contents
of the involved chromosomes and the analytical bias of the
sequencing platform in relation to the GC contents [31,32].
Nonetheless, the use of bioinformatics algorithms that correct
for such bias has been shown to allow the improved detection
of trisomies 13 and 18 [38,39]. The robust detection of triso-
mies 13 and 18 has recently been validated by a number of
large-scale studies [37,40,41]. The future use of single-
molecule sequencing platforms that do not require the use
of an amplification step might further reduce the influence
of the GC content and might improve the robustness of this
approach [42].
Asaresultofthevariouslarge-scalestudies,theuseofmas-
sively parallel sequencing of maternal plasma DNA for the
prenatal detection of foetal chromosomal aneuploidies has
been introduced as a clinical service in the USA and parts of
Asia. It is likely that this technology will be used clinically in
other regions around the world in the near future.
Thecost ofthistechnologyisstillrelativelyexpensivewhen
compared with conventional prenatal screening procedures,
but is comparable with the costs of invasive testing involving
amniocentesis. A number of groups have explored the possi-
bility of reducing the sequencing costs. Random sequencing
istheprotocolemployedbymostworkersinthefield,whereby
sequence tags will be obtained for all chromosomes [30,31].
Thenumberof sequence tags obtained perchromosome ispro-
portional to the size of each chromosome. In such a protocol,
only a proportion of the sequenced reads will align to the
chromosome of interest (e.g. chromosome 21).
In an effort to reduce the cost of sequencing, Liao et al.
[43] have demonstrated that a solution-based target capture
system is able to focus the sequencing power to selected
genomic regions. Such a system is able to increase the sequen-
cing coverage of the targeted region by over 200-fold.
Another system has recently been described by Sparks et al.
[44] in which hundreds of sets of oligonucleotides have
been used to target selected regions of the genome. These tar-
geted regions are then amplified and sequenced by massively
parallel sequencing. Following a process of normalization,
the authors have reported that trisomy 21 and 18 samples
are distinguishable from euploid samples. However, it is
important to note that the authors have only reported a train-
ing dataset, but have not tested the robustness of their
algorithm using a validation dataset. In a subsequent publi-
cation by the same group, the authors have introduced a
new algorithm whereby the fractional concentrations of
foetal DNA in maternal plasma are incorporated into the
data analysis step [45]. Nonetheless, they have not compared
the performance of this new algorithm with that of their pre-
vious algorithm [44]. The new algorithm, on the other hand,
has been tested in an independent cohort [46]. The relative
robustness of the selective chromosome sequencing approach
[46] and the previously described random sequencing
approach [30,31,34,36,37,39,41] would need to be evaluated
in future studies. The cost-effectiveness issue of the targeted
versus the non-targeted approach also needs to be addressed
in the context of the continual and rapid reduction in the
costs associated with sequencing.
6. Towards prenatal foetal whole
genome sequencing
In addition to the detection of foetal chromosomal aneuploi-
dies, the analytical precision offered by molecular counting
approaches such as digital PCR has implications for the
non-invasive prenatal diagnosis of monogenic diseases. For
example, in the situation of a mother who is a heterozygous
carrier of an autosomal recessive monogenic disease, the rela-
tive dosage of the mutant and normal versions of the gene in
the mother’s genome should be 1:1. However, when the
mother is pregnant with a foetus, then the relative dosage
of the two versions of the gene in the mother’s plasma will
be modified depending on the foetal genotype. If the foetus
is homozygous for the mutant gene, then the addition of
two doses of the mutant gene per genome-equivalent of
foetal DNA into the maternal plasma will bias the relative
dosage in favour of the mutant gene. If the foetus is homozy-
gous for the normal gene, then the relative dosage of the
mutant and normal genes in the mother’s plasma will be
biased in favour of the normal gene. Finally, if the foetus is
heterozygous, then the 1:1 relative dosage of the mutant
and normal genes will remain unchanged in the mother’s
plasma. This concept has been called the relative mutation
dosage approach [47], and has been used for the non-invasive
prenatal diagnosis of the haemoglobinopathies [47] and
haemophilia [48].
With the advent of massively parallel sequencing, thistype
of concept can be applied on a genome-wide scale. Thus, Lo
et al. [49] demonstrated that by sequencing maternal plasma
DNA to the equivalent of 65-fold haploid genome coverage,
a genome-wide genetic and mutational profile of a foetus can
be assembled from the sequencing data. The authors have
further used the genetic maps of the father and the mother to
help assemble the foetal genetic map. The resolution of the
foetal genomic map that one could assemble is limited by the
resolution of the parental genetic maps. This method thus
opens up the possibility that the prenatal diagnosis of multiple
geneticdiseases couldbeperformedbyasingletest.Thefuture
refinement of targeted sequencing approaches would be
expected to reduce the cost of this technology.
7. Conclusions
It is probable that non-invasive prenatal diagnosis using
foetal DNA in maternal plasma would play an increasingly
important role in the future practice of prenatal testing. How-
ever, it is important to address the ethical, legal and social
issues surrounding such developments [50–52]. The positive
side of non-invasive testing is the avoidance of harm to the
foetus that would be associated with invasive testing. How-
ever, some parties may be concerned by the possibility that
the availability of non-invasive testing might ‘encourage’
more pregnant women to undergo testing. Such issues, and
others, would need specially designed studies to systematically
address them.
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